Quadrant Capital Group’s West Pharmaceutical WST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $708K | Buy |
1,972
+10
| +0.5% | +$3.06K | 0.02% | 727 |
|
|
2026
Q1 | $492K | Sell |
1,962
-27
| -1% | -$6.72K | 0.01% | 904 |
|
|
2025
Q4 | $547K | Hold |
1,989
| – | – | 0.02% | 869 |
|
|
2025
Q3 | $522K | Buy |
1,989
+18
| +0.9% | +$4.38K | 0.02% | 854 |
|
|
2025
Q2 | $431K | Sell |
1,971
-653
| -25% | -$140K | 0.02% | 961 |
|
|
2025
Q1 | $587K | Buy |
2,624
+1,998
| +319% | +$551K | 0.02% | 630 |
|
|
2024
Q4 | $205K | Buy |
626
+32
| +5% | +$10.1K | 0.01% | 666 |
|
|
2024
Q3 | $178K | Sell |
594
-63
| -10% | -$19.3K | 0.01% | 764 |
|
|
2024
Q2 | $216K | Sell |
657
-125
| -16% | -$44.2K | 0.02% | 608 |
|
|
2024
Q1 | $309K | Sell |
782
-31
| -4% | -$11.5K | 0.02% | 456 |
|
|
2023
Q4 | $286K | Buy |
813
+11
| +1% | +$3.89K | 0.02% | 465 |
|
|
2023
Q3 | $301K | Buy |
802
+69
| +9% | +$26.7K | 0.03% | 396 |
|
|
2023
Q2 | $280K | Buy |
733
+18
| +3% | +$6.43K | 0.03% | 402 |
|
|
2023
Q1 | $248K | Buy |
715
+209
| +41% | +$61.1K | 0.03% | 442 |
|
|
2022
Q4 | $119K | Buy |
506
+13
| +3% | +$3.08K | 0.01% | 690 |
|
|
2022
Q3 | $121K | Sell |
493
-65
| -12% | -$19.8K | 0.02% | 604 |
|
|
2022
Q2 | $169K | Buy |
558
+85
| +18% | +$27.7K | 0.02% | 469 |
|
|
2022
Q1 | $194K | Buy |
473
+43
| +10% | +$16.8K | 0.02% | 457 |
|
|
2021
Q4 | $202K | Buy |
430
+60
| +16% | +$25.8K | 0.02% | 440 |
|
|
2021
Q3 | $157K | Buy |
370
+16
| +5% | +$6.75K | 0.02% | 468 |
|
|
2021
Q2 | $127K | Buy |
354
+16
| +5% | +$5.29K | 0.02% | 524 |
|
|
2021
Q1 | $95K | Buy |
338
+95
| +39% | +$27.2K | 0.02% | 594 |
|
|
2020
Q4 | $69K | Sell |
243
-37
| -13% | -$10.4K | 0.01% | 640 |
|
|
2020
Q3 | $77K | Buy |
280
+75
| +37% | +$19.8K | 0.02% | 519 |
|
|
2020
Q2 | $47K | Sell |
205
-411
| -67% | -$80.8K | 0.01% | 746 |
|
|
2020
Q1 | $95K | Buy |
616
+63
| +11% | +$9.7K | 0.02% | 605 |
|
|
2019
Q4 | $81K | Hold |
553
| – | – | 0.01% | 1091 |
|
|
2019
Q3 | $76K | Hold |
553
| – | – | 0.01% | 1036 |
|
|
2019
Q2 | $66K | Buy |
553
+235
| +74% | +$27.7K | 0.01% | 1080 |
|
|
2019
Q1 | $32K | Buy |
318
+215
| +209% | +$22.4K | 0.01% | 1373 |
|
|
2018
Q4 | $9K | Hold |
103
| – | – | ﹤0.01% | 1441 |
|
|
2018
Q3 | $11K | Hold |
103
| – | – | ﹤0.01% | 1251 |
|
|
2018
Q2 | $9K | Buy |
103
+1
| +1% | +$92 | ﹤0.01% | 1329 |
|
|
2018
Q1 | $8K | Hold |
102
| – | – | ﹤0.01% | 1371 |
|
|
2017
Q4 | $9K | Hold |
102
| – | – | ﹤0.01% | 1235 |
|
|
2017
Q3 | $9K | Buy |
102
+26
| +34% | +$2.35K | ﹤0.01% | 1236 |
|
|
2017
Q2 | $2K | Hold |
76
| – | – | ﹤0.01% | 1625 |
|
|
2017
Q1 | $5K | Buy |
76
+53
| +230% | +$4.43K | ﹤0.01% | 1347 |
|
|
2016
Q4 | $1K | Hold |
23
| – | – | ﹤0.01% | 1838 |
|
|
2016
Q3 | $1K | Hold |
23
| – | – | ﹤0.01% | 1823 |
|
|
2016
Q2 | $1K | Buy |
+23
| New | +$1.67K | ﹤0.01% | 1801 |
|
Other funds holding WST
GIM
Quadrant Capital Group's WST Position: Q2 2026 in Review
Quadrant Capital Group increased its West Pharmaceutical (WST) stake by 0.51% in Q2 2026, buying an estimated $3.06K and bringing the position to 1,972 shares worth $708K. The position accounts for 0.02% of the portfolio, ranked #727.
Quadrant Capital Group first reported a position in WST in Q2 2016 and has held it in 41 quarters since. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.
- Quadrant Capital Group held 1,972 shares of West Pharmaceutical worth $708K as of Q2 2026.
- Quadrant Capital Group bought 10 West Pharmaceutical shares in Q2 2026, an estimated $3.06K.
- West Pharmaceutical made up 0.02% of Quadrant Capital Group's portfolio in Q2 2026, its #727 holding.
- Quadrant Capital Group first reported a position in West Pharmaceutical in Q2 2016 and has held it in 41 quarters since.
- 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.
Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.